UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 557

Sortiert nach

If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia

Journal of thrombosis and haemostasis, 2017-06, Vol.15 (6), p.1103-1105

Berntorp, E.

2017

Link zum Volltext

Verfügbarkeit prüfen

Replacement therapy during surgery in von Willebrand disease needs personalization

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (3), p.338-340

Berntorp, E.

2018

Link zum Volltext

Verfügbarkeit prüfen

Haemophilia treatment in 2030

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (S5), p.15-19

Berntorp, E.

2016

Link zum Volltext

Verfügbarkeit prüfen

Future of haemophilia outcome assessment: registries are key to optimized treatment

Journal of internal medicine, 2016-06, Vol.279 (6), p.498-501

Berntorp, E.

2016

Link zum Volltext

Verfügbarkeit prüfen

Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-01, Vol.15 (1), p.3-10

BERNTORP, E.

2009

Link zum Volltext

Verfügbarkeit prüfen

Defining extended half‐life rFVIII—A critical review of the evidence

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (3), p.348-358

2018

Link zum Volltext

Verfügbarkeit prüfen

Immune tolerance induction: What have we learned over time?

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-04, Vol.24 (S3), p.3-14

2018

Link zum Volltext

Verfügbarkeit prüfen

Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-11, Vol.15 (6), p.1219-1227

BERNTORP, E.

2009

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors in haemophilia: what have we learned from registries? A systematic review

Journal of internal medicine, 2015-01, Vol.277 (1), p.1-15

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-11, Vol.19 (6), p.805-807

Berntorp, E.

2013

Link zum Volltext

Verfügbarkeit prüfen

Registry‐based outcome assessment in haemophilia: a scoping study to explore the available evidence

Journal of internal medicine, 2016-06, Vol.279 (6), p.502-514

2016

Link zum Volltext

Verfügbarkeit prüfen

Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate®, a new generation von Willebrand factor/factor VIII concentrate

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-01, Vol.15 (1), p.122-130

2009

Link zum Volltext

Verfügbarkeit prüfen

History of prophylaxis

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-03, Vol.19 (2), p.163-165

Berntorp, E.

2013

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of plasma‐derived factor IX: procedures for dose individualization

Journal of thrombosis and haemostasis, 2016-04, Vol.14 (4), p.724-732

2016

Link zum Volltext

Verfügbarkeit prüfen

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.514-520

2016

Link zum Volltext

Verfügbarkeit prüfen

Preference‐based valuation of treatment attributes in haemophilia A using web survey

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-11, Vol.23 (6), p.894-903

2017

Link zum Volltext

Verfügbarkeit prüfen

Bleeding‐related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.628-633

2018

Link zum Volltext

Verfügbarkeit prüfen

Hypertension and cardiovascular diseases in Swedish persons with haemophilia — A longitudinal registry study

Thrombosis research, 2019-09, Vol.181 (Sept.), p.106-111

2019

Link zum Volltext

Verfügbarkeit prüfen

Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network

Journal of thrombosis and haemostasis, 2015-09, Vol.13 (9), p.1585-1589

2015

Link zum Volltext

Verfügbarkeit prüfen

Prophylaxis in von Willebrand disease

Haemophilia : the official journal of the World Federation of Hemophilia, 2008-11, Vol.14 (s5), p.47-53

BERNTORP, E.

2008

Link zum Volltext

Verfügbarkeit prüfen

No difference in quality of life between persons with severe haemophilia A and B

Haemophilia : the official journal of the World Federation of Hemophilia, 2023-07, Vol.29 (4), p.987-996

2023

Link zum Volltext

Verfügbarkeit prüfen

Joint comorbidities among Swedish carriers of haemophilia: A register‐based cohort study over 22 years

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-09, Vol.25 (5), p.845-850

2019

Link zum Volltext

Verfügbarkeit prüfen

Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-05, Vol.22 (3), p.389-396

2016

Link zum Volltext

Verfügbarkeit prüfen

Quality of life in adult patients with haemophilia - a single centre experience from Sweden

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (4), p.527-531

2012

Link zum Volltext

Verfügbarkeit prüfen

Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-01, Vol.19 (1), p.76-81

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 557

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(387)
Mit Volltextzugriff
(480)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(31)

Menü

Weitere Dienste

Einstellungen

If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia

Replacement therapy during surgery in von Willebrand disease needs personalization

Haemophilia treatment in 2030

Future of haemophilia outcome assessment: registries are key to optimized treatment

Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors

Defining extended half‐life rFVIII—A critical review of the evidence

Immune tolerance induction: What have we learned over time?

Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens

Inhibitors in haemophilia: what have we learned from registries? A systematic review

Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study

Registry‐based outcome assessment in haemophilia: a scoping study to explore the available evidence

Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate®, a new generation von Willebrand factor/factor VIII concentrate

History of prophylaxis

Population pharmacokinetics of plasma‐derived factor IX: procedures for dose individualization

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

Preference‐based valuation of treatment attributes in haemophilia A using web survey

Bleeding‐related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network

Hypertension and cardiovascular diseases in Swedish persons with haemophilia — A longitudinal registry study

Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network

Prophylaxis in von Willebrand disease

No difference in quality of life between persons with severe haemophilia A and B

Joint comorbidities among Swedish carriers of haemophilia: A register‐based cohort study over 22 years

Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc

Quality of life in adult patients with haemophilia - a single centre experience from Sweden

Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)

Suchergebnisse filtern